Výsledky vyhledávání - "J G Cairncross"

p53‐dependent up‐regulation of CDKN 1A and down‐regulation of CCNE 2 in response to beryllium

Autor: J. G. Cairncross, Ronald K. Gary, Priyatham Gorjala

Publikováno v: Cell Proliferation. 49:698-709

Objectives Beryllium salts (here, beryllium sulphate) can produce a cytostatic effect in some cell types. The basis for this effect may include increased expression of proliferation inhibitors, reduced expression of proliferation promoters, or both.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8c0f27408ae2ec6fe97f8e13018403ab
https://doi.org/10.1111/cpr.12291

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Oligodendroglioma, IDH-mutant and 1p/19q-codeleted.

Autor: G., Reifenberger, J. G., Cairncross, D., Figarella-Branger, C., Hartmann, J. M., Kros, D. N., Louis, M., Snuderl, M. L., Suvà, M. J., Van Den Bent, S., Yip, H., Yokoo

Publikováno v: WHO/IARC Classification of Tumours; 2021, Vol. 6, p28-38, 11p

Zobrazit plný text záznamu

DRES-04. CHARACTERIZATION OF A MODEL OF TEMOZOLOMIDE RESISTANCE IN GLIOBLASTOMA

Autor: J. G. Cairncross, Michael D. Blough, Elizabeth A. Bering, Alice Yuan

Despite the discovery and widespread use of the chemotherapeutic drug temozolomide (TMZ), glioblastoma (GBM) remains a fatal cancer. TMZ, a DNA alkylating agent, provides a moderate survival benefit to patients whose tumours do not express the O6-met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6068812291fc2559572dc30bd0a9a568
https://europepmc.org/articles/PMC6216400/

Zobrazit plný text záznamu

1450-1545 Young Investigator Awards & Presentations Basic/Translational Exploring cellular subpopulations in glioblastoma and matched organoids using single-cell RNA-seq 52

Autor: Blough, John Kelly, D. Livingstone, I Luthra, Martha Hughes, Veronique G. LeBlanc, J. G. Cairncross, D. L. Trinh, Marco A. Marra

Publikováno v: Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 45:S13-S14

Glioblastomas (GBMs) account for nearly half of all primary malignant brain tumours, and current therapies are often only marginally effective. Our understanding of the underlying biology of these tumours and the development of new therapies have bee

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::de4fd1f71ca8fa750a0a0ee32ee1605a
https://doi.org/10.1017/cjn.2018.297

Zobrazit plný text záznamu

LAB-STEM CELLS

Autor: D. Kozono, M. Nitta, O. Sampetrean, N. Kimberly, D. Kushwaha, D. Merzon, K. Ligon, S. Zhu, K. Zhu, T. H. Kim, C.-H. Kwon, O. Becher, H. Saya, C. C. Chen, L. K. Donovan, S. M. Birks, V. Bosak, G. J. Pilkington, P. Mao, J. Li, K. Joshi, B. Hu, S. Cheng, R. W. Sobol, I. Nakano, M. Li, J. S. Hale, J. T. Myers, A. Y. Huang, C. Gladson, A. A. Sloan, J. N. Rich, J. D. Lathia, P. E. Hall, J. Gallagher, Q. Wu, M. Venere, E. Levy, M. S. Rani, P. Huang, E. Bae, J. Selfridge, L. Cheng, H. Guvenc, R. E. McLendon, A. E. Sloan, H. Phillips, A. Lai, M. Bredel, S. Bao, A. Hjelmeland, M. Sinyuk, P. Sathyan, J. Hale, P. Zinn, C. T. Carson, U. Naik, S. Majumder, L. A. Song, A. Vasanji, N. Tenley, A. B. Hjelmeland, P. Peruzzi, A. Bronisz, E. Antonio Chiocca, J. A. Godlewski, O. A. Guryanova, X. Fang, H.-M. C. Christel, C. Benito, G. Zoltan, B. Aline, S. Tilman, B. Josephine, M. Carolin, S. Thomas, G. Violaine, A. Unterberg, V. Capilla-Gonzalez, H. Guerrero-Cazares, A. Cebrian-Silla, J. M. Garcia-Verdugo, A. Quinones-Hinojosa, J. Man, J. Shoemake, J. Rich, J. Yu, X. He, F. DiMeco, A. L. Vescovi, J. A. Heth, K. M. Muraszko, X. Fan, S. A. Nguyen, O. D. Stechishin, H. A. Luchman, J. J. Kelly, J. G. Cairncross, S. Weiss, Y. Kim, E. Kim, O. O. Guryanova, M. Hitomi, J. Lathia, D. Serwanski, J. Robert, J. Lee, A. Nishiyama, J. K. Liu, W. A. Flavahan, N. Fernandez, M. Wu, S. Das, E. Bazzoli, T. Pulvirenti, M. C. Oberstadt, F. Perna, W. Boyoung, N. Schultz, J. T. Huse, E. I. Fomchenko, F. Voza, V. Tabar, C. W. Brennan, L. M. DeAngelis, S. D. Nimer, E. C. Holland, M. Squatrito, Y.-H. Chen, D. H. Gutmann, S.-H. Kim, M. K. Lee, Y.-J. Chwae, B. C. Yoo, K.-H. Kim, A. Soeda, A. Hara, T. Iwama, D. M. Park, A. Golebiewska, S. Bougnaud, D. Stieber, N. H. Brons, L. Vallar, F. Hertel, R. Bjerkvig, S. P. Niclou, P. Hamerlik, R. Rasmussen, D. Fricova, B. Jiri, A. Schulte, A. Kathagen, S. Zapf, H. Meissner, H. S. Phillips, M. Westphal, K. Lamszus, M. Sanzey, S. K. Singh, A. Vartanian, J. Gumin, E. P. Sulman, F. F. Lang, G. Zadeh, N. S. Bayin, A. Dietrich, T. Abel, M. V. Chao, H.-R. Song, C. J. Buchholz, D. Placantonakis, M. Esencay, D. Zagzag, I. V. Balyasnikova, M. S. Prasol, S. D. Ferguson, A. U. Ahmed, Y. Han, M. S. Lesniak, M. E. Barish, C. E. Brown, K. Herrmann, S. Argalian, M. Gutova, Y. Tang, A. Annala, R. A. Moats, L. Y. Ghoda, K. S. Aboody, S. Gadani, J. Adkins, A. Vsanji, R. McLendon, A. Chenn, D. Park, C. Dictus, S. Friauf, N. A. Valous, N. Grabe, B. Muerle, A. W. Unterberg, C. C. Herold-Mende, H. K. Lee, S. Finniss, E. Buchris, A. Ziv-Av, S. Casacu, C. Xiang, K. Bobbit, S. A. Rempel, T. Mikkelsen, S. Slavin, C. Brodie, D.-H. Woo, Y. Oh, M. Kim, D.-H. Nam, Q. Li, S. Salas, C. Pendleton, O. Wijesekera, D. Chesler, J. Wang, C. Smith, A. Levchenko, Q. LaPlant, K. Pitter, A.-M. Bleau, K. Helmy, J. Werbeck, L. Barrett, F. Shimizu, R. Benezra, E. Holland, Q. Chu, E. Bar, B. Orr, C. G. Eberhart, R. S. Schmid, R. E. Bash, A. M. Werneke, K. K. White, C. R. Miller, F. Agasse, N. Jhaveri, F. M. Hofman, T. C. Chen, A. Natsume, T. Wakabayashi, Y. Kondo, N. Chang, E. Moon, R. Kanai, S. Yip, A. Kimura, S. Tanaka, E. Rheinbay, D. Cahill, W. Curry, G. Mohapatra, J. Iafrate, A. Chi, R. Martuza, S. Rabkin, H. Wakimoto, C. Cusulin, J. A. Frank, A. J. Annala

Publikováno v: Neuro-Oncology. 14:vi142-vi152

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9f3d11540e8126662b7e649f3dc5f58
https://doi.org/10.1093/neuonc/nos239

Zobrazit plný text záznamu

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma

Autor: René-Olivier Mirimanoff, Charles J. Vecht, Peter A. Forsyth, J. G. Cairncross, Thierry Gorlia, Andrea O. Rossetti, Warren P. Mason, David R. Macdonald, Roger Stupp, Karl Belanger, Alba A. Brandes, M. J. van den Bent, Ulrich Bogdahn, Denis Lacombe, Michael Weller

Publikováno v: Neurology, 77(12), 1156-1164. Lippincott Williams & Wilkins

Objective: This analysis was performed to assess whether antiepileptic drugs (AEDs) modulate the effectiveness of temozolomide radiochemotherapy in patients with newly diagnosed glioblastoma. Methods: The European Organization for Research and Treatm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b003cf33fa39f57a5ce77f04edf571e7
https://doi.org/10.1212/wnl.0b013e31822f02e1

Zobrazit plný text záznamu

21 Inhibiting PARP-1 to restore temozolomide sensitivity and prevent resistance in glioblastoma

Autor: J. G. Cairncross, A. L. Yuan, E. A. Bering, M. D. Blough

Publikováno v: Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 45:S4-S4

Adult Glioblastomas (GBMs) remain one of the least curable brain cancers despite the discovery and use of DNA alkylating agent Temozolomide (TMZ). TMZ provides a moderate survival benefit to sensitive patients whose O6-methylguanine-methyltransferase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cb559a611f60183d66266e484ff54066
https://doi.org/10.1017/cjn.2018.309

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání